Jump to content

CYLD (gene)

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

CYLD
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCYLD, BRSS, CDMT, CYLD1, CYLDI, EAC, MFT, MFT1, SBS, TEM, USPL2, CYLD lysine 63 deubiquitinase
External IDsOMIM: 605018; MGI: 1921506; HomoloGene: 9069; GeneCards: CYLD; OMA:CYLD - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001042355
NM_001042412
NM_015247

NM_001128169
NM_001128170
NM_001128171
NM_001276279
NM_173369

RefSeq (protein)

NP_001121642
NP_001121643
NP_001263208
NP_775545

Location (UCSC)Chr 16: 50.74 – 50.8 MbChr 8: 89.42 – 89.48 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

The CYLD lysine 63 deubiquitinase gene, also termed the CYLD gene,[5] CYLD is an evolutionary ancient gene found to be present as far back on the evolutionary scale as in sponges.[6] In humans, this gene is located in band 12.1 on the long (or "q") arm of chromosome 16[7] and is known to code (i.e. direct the production of) multiple proteins through the process of alternative splicing.[8]

The CYLD gene in known to code for a cytoplasmic protein, termed CYLD lysine 63 deubiquitinase (here termed CYLD protein), which has three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains (areas or the protein controlling critical functions[9]). CYLD protein is a deubiquitinating enzyme, i.e. a protease that removes ubiquitin from certain proteins and thereby regulates these proteins' activities. CYLD protein removes ubiquitin from proteins involved in regulating the NF-κB, Wnt, notch, TGF-β,[10] and JNK[11] cell signaling pathways; these pathways normally act to regulate hair formation, cell growth, cell survival, inflammatory responses, and/or tumor development.[10][11]

The CYLD gene is classified as a tumor suppressor gene, i.e. a gene that regulates cell growth and when inactivated by a mutation leads to uncontrolled cell growth and the formation of tumors.[12] Inactivating mutations in this gene occur in essentially all cases of the CYLD cutaneous syndrome, a hereditary disorder in which individuals develop multiple skin tumors. The CYLD cutaneous syndrome includes three somewhat different forms of the disease: the multiple familial trichoepithelioma-type, Brooke–Spiegler syndrome-type, and familial cylindromatosis-type.[10] CYLD gene mutations are also associated with T-Cell Acute Lymphoblastic Leukemia,[12] multiple myeloma, hepatocellular carcinoma, neuroblastoma, pancreatic cancer,[13] uterine cancer, stomach cancer, colon cancer, lung cancer, and human papillomavirus-associated cancers.[11]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000083799Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000036712Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ "Symbol report for CYLD". www.genenames.org/. Retrieved 20 June 2019.
  6. ^ Hadweh P, Chaitoglou I, Gravato-Nobre MJ, Ligoxygakis P, Mosialos G, Hatzivassiliou E (2018). "Functional analysis of the C. elegans cyld-1 gene reveals extensive similarity with its human homolog". PLOS ONE. 13 (2): e0191864. Bibcode:2018PLoSO..1391864H. doi:10.1371/journal.pone.0191864. PMC 5796713. PMID 29394249.
  7. ^ Arruda AP, Cardoso-Dos-Santos AC, Mariath LM, Feira MF, Kowalski TW, Bezerra KR, da Silva LA, Ribeiro EM, Schuler-Faccini L (July 2020). "A large family with CYLD cutaneous syndrome: medical genetics at the community level". Journal of Community Genetics. 11 (3): 279–284. doi:10.1007/s12687-019-00447-2. PMC 7295879. PMID 31792733.
  8. ^ "Entrez Gene: CYLD cylindromatosis (turban tumor syndrome)".
  9. ^ Weisbrich A, Honnappa S, Jaussi R, Okhrimenko O, Frey D, Jelesarov I, Akhmanova A, Steinmetz MO (October 2007). "Structure-function relationship of CAP-Gly domains". Nature Structural & Molecular Biology. 14 (10): 959–67. doi:10.1038/nsmb1291. PMID 17828277. S2CID 37088265.
  10. ^ a b c Nagy N, Dubois A, Szell M, Rajan N (2021). "Genetic Testing in CYLD Cutaneous Syndrome: An Update". The Application of Clinical Genetics. 14: 427–444. doi:10.2147/TACG.S288274. PMC 8566010. PMID 34744449.
  11. ^ a b c Cui Z, Kang H, Grandis JR, Johnson DE (January 2021). "CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers". Molecular Cancer Research. 19 (1): 14–24. doi:10.1158/1541-7786.MCR-20-0565. PMC 7840145. PMID 32883697.
  12. ^ a b Lei H, Wang J, Hu J, Zhu Q, Wu Y (August 2021). "Deubiquitinases in hematological malignancies". Biomarker Research. 9 (1): 66. doi:10.1186/s40364-021-00320-w. PMC 8401176. PMID 34454635.
  13. ^ Davies HR, Hodgson K, Schwalbe E, Coxhead J, Sinclair N, Zou X, Cockell S, Husain A, Nik-Zainal S, Rajan N (October 2019). "Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome". Nature Communications. 10 (1): 4717. Bibcode:2019NatCo..10.4717D. doi:10.1038/s41467-019-12746-w. PMC 6797807. PMID 31624251.

Further reading